Armand de Gramont
Armand is one of the three founders and CSO of Onward Therapeutics SA since its inception in November 2019.
From 2016 to 2019, he was Vice President Translational Sciences at PharmaEngine. From 2014 to 2016, he was Head of a research laboratory in the Oncology Department of the Lausanne University Hospital (CHUV), Switzerland. From 2011 to 2014, he served as COO at AFR Oncology, a small biotechnology company in France.
Prior to that, he worked for several years as a consultant in oncology drug evaluation and in fundamental research at the National Institute of Health (NIH), Bethesda, USA. He currently serves on the board of EMERCell SAS.
Armand received his Ph.D. in cellular biochemistry from Paris Sorbonne University, France.